Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KLK3 | P07288 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746464 | 1.00 | TDP1 (0.55) | TDP1TSHRSMN1; SMN2HSD17B10JAK2 | |
| SCHEMBL7690779 | 0.85 | HSD17B10 (0.44) | TDP1TSHRSMN1; SMN2HSD17B10L3MBTL1 | |
| SCHEMBL31130611 | 0.85 | HSD17B10 (0.44) | TDP1TSHRSMN1; SMN2HSD17B10L3MBTL1 | |
| SCHEMBL29766546 | 0.83 | TDP1 (0.41) | TDP1TSHRSMN1; SMN2HSD17B10JAK2 | |
| SCHEMBL20681552 | 0.83 | TDP1 (0.55) | TDP1TSHRSMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL30129134 | 0.83 | TDP1 (0.55) | TDP1TSHRSMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL8222838 | 0.83 | TDP1 (0.41) | TDP1TSHRSMN1; SMN2HSD17B10JAK2 | |
| SCHEMBL1706340 | 0.81 | TDP1 (0.41) | TDP1TSHRSMN1; SMN2HSD17B10L3MBTL1 | |
| SCHEMBL29744902 | 0.81 | TDP1 (0.41) | TDP1TSHRSMN1; SMN2HSD17B10L3MBTL1 | |
| SCHEMBL1066079 | 0.81 | TDP1 (0.50) | TDP1TSHRSMN1; SMN2HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981839-B1 | COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-02-22 | — | — | US | disclosed |
| CN-112513188-B | Coelenterazine analogs | 普洛麦格公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2024010925-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| CN-112513188-A | Coelenterazine analogs | 普洛麦格公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| CN-106220614-B | Pyridone/pyrazinones, preparation method and application method | 吉利德康涅狄格有限公司 | 2019-07-16 | — | — | CN | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| WO-2009039397-A2 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | CGI PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039397-A2 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | CGI PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | TDP1 3852/4885TSHR 2341/4885SMN1; SMN2 3970/4885 |
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | TDP1 3852/4885TSHR 2341/4885SMN1; SMN2 3970/4885 |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | TDP1 3852/4885TSHR 2341/4885SMN1; SMN2 3970/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | TDP1 1696/4885TSHR 2514/4885SMN1; SMN2 3454/4885 |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | TDP1 1109/4885TSHR 2774/4885SMN1; SMN2 3343/4885 |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, TK1 | TDP1 48/4885TSHR 3516/4885SMN1; SMN2 2860/4885 |
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | TDP1 548/4885TSHR 1932/4885SMN1; SMN2 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.